Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
August 31, 2022 07:34 AM EDTUpdated 08:34 AM
Pharma
Law

No­var­tis' En­tresto in­fringes on uni­ver­si­ty patents, law­suit claims

Paul Schloesser

Associate Editor

More than a year and a half af­ter se­cur­ing FDA ap­proval for a block­buster heart drug, No­var­tis is now go­ing to court over it. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times